Evidence map›Paper›PMID 21233309›Full record

ArticleJournal of biomolecular screening2011

A high-content screening (HCS) assay for the identification of chemical inducers of PML oncogenic domains (PODs).

Kenneth W Yip, Michael Cuddy, Clemencia Pinilla, Marc Giulanotti, Susanne Heynen-Genel, Shu-ichi Matsuzawa, John C Reed

Open access · hybridAbstract read
In one paragraph

Article in Journal of biomolecular screening, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. High throughput toxicity screening and intracellular detection of nanomaterials.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2017
    Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Kenneth W YipSanford-Burnham Medical Research Institute, La Jolla, CA 92037, USA.
Michael Cuddy
Clemencia Pinilla
Marc Giulanotti
Susanne Heynen-Genel
Shu-ichi Matsuzawa
John C Reed
Sanford Burnham Prebys Medical Discovery Institute · USTorrey Pines Institute For Molecular Studies · USUniversity of Toronto · CA

Funding

THE THERAPY OF AMLP01CA055164 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI THOMAS, MATTIE J · 1992 to 2011
$25.3M
Virulence Mechanisms of Viral Bcl-2 HomologsR01AI091967 · NIAID · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI MATSUZAWA, SHU-ICHI · 2011 to 2015
$2.4M
NCI NIH HHS CA-55164NCI NIH HHS P01 CA055164NIAID NIH HHS R01 AI091967
6 · The paper itself

Abstract

PML is a multi-functional protein with roles in tumor suppression and host defense against viruses. When active, PML localizes to subnuclear structures named PML oncogenic domains (PODs) or PML nuclear bodies (PML-NBs), whereas inactive PML is located diffusely throughout the nucleus of cells. The objective of the current study was to develop a high content screening (HCS) assay for the identification of chemical activators of PML. We describe methods for automated analysis of POD formation using high throughput microscopy (HTM) to localize PML immunofluorescence in conjunction with image analysis software for POD quantification. Using this HCS assay in 384 well format, we performed pilot screens of a small synthetic chemical library and mixture-based combinatorial libraries, demonstrating the robust performance of the assay. HCS counter-screening assays were also developed for hit characterization, based on immunofluorescence analyses of the subcellular location of phosphorylated H2AX or phosphorylated CHK1, which increase in a punctate nuclear pattern in response to DNA damage. Thus, the HCS assay devised here represents a high throughput screen that can be utilized to discover POD-inducing compounds that may restore the tumor suppressor activity of PML in cancers or possibly promote anti-viral states.

Indexed as

High-Throughput Screening AssaysAntineoplastic AgentsAntiviral AgentsCell LineDrug DiscoveryHeLa CellsHumansMicroscopy, FluorescenceNuclear ProteinsPromyelocytic Leukemia ProteinProtein BindingProtein TransportReproducibility of ResultsSensitivity and SpecificityTranscriptional ActivationTranscription FactorsAntineoplastic AgentsAntiviral AgentsCALCOCO2 protein, humanNuclear ProteinsPML protein, humanPromyelocytic Leukemia ProteinTranscription FactorsTumor Suppressor Proteins

Identifiers

PMID21233309
PMCPMC4172586
OpenAlexW2098657179

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.